SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
The SAB is led by Peter J. Fitzgerald, MD, PhD, the company’s Chief Medical Officer and C. Michael Gibson, MD, previously announced as SAB Chair. Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
Dr. Gibson is President and CEO of the Baim Institute for Clinical Research, Professor of Medicine, Harvard Medical School and Interventional Cardiologist at Beth Israel Deaconess Medical Center. He is a cardiovascular researcher, and educator who pioneered understanding of the “open artery hypothesis” as well as understanding of the importance of restoring flow downstream in the capillary bed in the “open microvasculature hypothesis” in a heart attack.
The newly announced members of the HeartBeam SAB are:
- Charles L. Brown III, MD, CEO of the Piedmont Healthcare Physician Enterprise, which is made up of Piedmont Heart, Piedmont Medical Care Corp., the Piedmont Clinic and other clinical programs. Dr. Brown is responsible for all aspects of clinical services and care delivered by Piedmont’s Physician Enterprise. He is an interventional cardiologist who previously served as Chief of Cardiovascular Services for the Piedmont Heart Institute.
- Tony Das, MD, a nationally recognized board-certified interventional cardiology specialist, leader, and educator in the field of cardiovascular diseases. Dr. Das founded Connected Cardiovascular Care in Dallas, the first Cardiology practice in the country dedicated to individualizing each patient’s care with state-of-the-art remote digital monitoring technology. Dr. Das is the Chief of Strategic Planning and Development and Medical Director of Digital Health, Innovation and Endovascular Services for Baylor Scott and White, The Heart Hospital Enterprise Plano.
- Robert Harrington, MD, Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. Dr. Harrington was previously chair of the Department of Medicine at Stanford University and is a past president of the American Heart Association. He is an accomplished cardiologist, with research areas of focus that include evaluating antithrombotic therapies to treat acute ischemic heart disease and trying to better understand and improve upon the methodology of clinical research.
- Campbell Rogers, MD, Executive Vice President and Chief Medical Officer at HeartFlow Inc. Dr. Rogers is an interventional cardiologist with a wealth of experience in research, teaching, and in industry. He previously served as Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, Associate Professor of Medicine at Harvard Medical School, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital.
- Niraj Varma, MD, Ph.D., Professor of Medicine and consultant electrophysiologist at the Cleveland Clinic. Dr. Varma specializes in the treatment of heart arrhythmias, with interests in ablation for atrial fibrillation and ventricular tachycardia, defibrillator implantation, and biventricular pacing. He has led first clinical use of several novel technologies e.g., electrocardiographic imaging (ECGI), cardiac resynchronization algorithms, and cryoablation. He pioneered the application of remote monitoring of implantable devices, chairing the landmark TRUST randomized trial. The results have been pivotal and adopted widely to improve the care of patients receiving such cardiac devices worldwide. He has served on Heart Rhythm Society Scientific and clinical documents and Digital Health committees. He is past President of the International Society of Holter and Non-Invasive Electrocardiography. He has developed and chaired several professional society guidelines on remote monitoring over the last decade.
“We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam. “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies. We look forward to working closely with all the SAB members as we advance our product development, clinical, and commercial efforts.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (VECG), the HeartBeam platform enables patients and their clinicians to assess their cardiac symptoms quickly and easily, so care can be expedited, if required. HeartBeam AIMIGo™ is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote evaluation of cardiac symptoms. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the US Food and Drug Administration (FDA) for marketing in the USA or other geographies. For more information, visit HeartBeam.com.
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.